2009; Alvarez-Jimenez et al. 2008; Tschoner et al. 2007; Kelly et al. 2005; Llorca et al. 2002; Allison and Casey, 2001; Muench and Carey,

2001]. This higher sensitivity to adverse events (AEs) coupled with poor adherence to selleck Bortezomib treatment are believed to be major contributors to relapse and the substantial deterioration that occurs early in the course of this chronic disease [Gilmer et al. 2004; Valenstein et al. 2004; Menzin et al. 2003; Coldham et al. 2002; Robinson et al. 1999]. In those at risk for poor adherence to daily therapy, the use of a long-acting injectable agent, if well tolerated, may be particularly beneficial. It has been suggested that Inhibitors,research,lifescience,medical long-acting injectable antipsychotics are a particularly appropriate treatment option in recently diagnosed patients in whom optimal therapeutic outcomes may be compromised by early treatment discontinuation and/or poor treatment adherence [Chue and Emsley, Inhibitors,research,lifescience,medical 2007; Keith and Kane, 2003]. Data from studies in patients with first episode [Kim et al. 2008] and recent onset psychosis [Emsley et al. 2008; Parellada et al. 2005] indicate that treatment with long-acting injectable antipsychotic agents may improve outcomes in patients with early disease symptoms. Paliperidone Abiraterone cost palmitate is a long-acting,

once-monthly Inhibitors,research,lifescience,medical (following two initiation doses given 1week apart) injectable, atypical, antipsychotic for the treatment of adults with schizophrenia. It is the palmitate ester of paliperidone, which is also formulated for daily oral administration as paliperidone extended Inhibitors,research,lifescience,medical release (ER). The dosage of paliperidone palmitate may be expressed as milligram equivalents (mgeq) of the pharmacologically active fraction, paliperidone (Table 1). Table 1. Corresponding dose expression equivalents of paliperidone and paliperidone palmitate. The Inhibitors,research,lifescience,medical efficacy and tolerability of paliperidone palmitate for the acute and maintenance treatment

of schizophrenia has been studied in several controlled clinical studies using various dosing regimens [Gopal et al. 2010; Hough et al. 2010, 2009; Nasrallah, et al. 2010; Pandina et al. 2010]. A recently completed phase 3 acute treatment trial was the first placebo-controlled study to assess paliperidone palmitate administered at the recommended day 1 dose of 150mgeq (234mg) by deltoid injection. Patients then received 25, 100, or 150mgeq (39, 156, or 234mg respectively) on day 8 and monthly thereafter (deltoid or gluteal). In this study, paliperidone palmitate was associated with significant Drug_discovery improvements in symptomatology with no unexpected tolerability findings in adults with symptomatic schizophrenia, at all doses tested [Pandina et al. 2010]. A post hoc analysis of this trial examined the recently diagnosed subgroup to assess the effects associated with the initiation doses [150mgeq (234mg) on day 1 and 100mgeq (156mg) on day 8], which may pose a tolerability concern when managing patients early in the course of their illness.